From April and the NIH...
https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/fluvoxamine/
“There is insufficient evidence for the COVID-19 Treatment Guidelines Panel to recommend either for or against the use of fluvoxamine for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of fluvoxamine for the treatment of COVID-19.”
If the NIH don’t like it, there must be something to it.